Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Geneart to Sell Synthetic Genes for Protein Production

NEW YORK (GenomeWeb News) – Qiagen and German gene synthesis company Geneart announced today that they are collaborating to commercialize a set of plasmids containing synthetic genes representing the entire human genome.
The QIAgenes plasmids will allow researchers to produce large quantities of some 35,000 human proteins. The product stems from a joint research and development project between Qiagen and Geneart, wherein Geneart contributed plasmid and gene synthesis technology and Qiagen supplied automated protein purification technology.
According to Qiagen, validation experiments done on 100 proteins indicate that the QIAgenes have success rates exceeding 90 percent and yield 50 times more protein than conventional methods, resulting from optimized synthetic genes and purification methods.
“In the past, researchers faced a multiple bottleneck situation when producing protein in sufficient quantity and quality for their research,” Kai te Kaat, Qiagen's global business director for proteins, said in a statement. “With the new QIAgenes product portfolio … our customers can now access the human proteome with a simple mouse click and significantly increase their successes expressing and purifying their protein of choice.”

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.